What You Should Know:– PathAI, a provider of AI-powered pathology solutions, today announced the launch of PathAssist Derm, an innovative tool designed to streamline the analysis of skin lesions.– Available now on the AISight® Image Management System (IMS), this research tool automates specimen orientation and identification, enabling pathologists to review samples more efficiently and accurately.PathAssist Derm CapabilitiesPathAssist Derm is the latest addition to PathAI’s suite of AI-powered solutions available on the AISight® IMS. This comprehensive platform provides pathologists with a range of tools to streamline their workflows and improve diagnostic accuracy. PathAssist Derm offers several key capabilities:Automated Specimen Orientation: Eliminates the need for manual orientation of glass slides, saving pathologists valuable time and reducing the risk of errors.Eliminates the need for manual orientation of glass slides, saving pathologists valuable time and reducing the risk of errors. Lesion Identification: Predicts the presence of 17 different skin lesion entities, including common and rare conditions, aiding in diagnosis and research.Predicts the presence of 17 different skin lesion entities, including common and rare conditions, aiding in diagnosis and research. Detailed Measurements: Provides precise measurements of lesion size and characteristics, facilitating quantitative analysis.“Skin cancer remains the most prevalent cancer worldwide, with over 1.5 million new cases diagnosed annually, which are associated with 60,000 deaths from melanoma alone,” said Andrew Beck, Co-Founder & CEO of PathAI. “These statistics present a critical opportunity for innovation in skin cancer research, both in the diagnostic and therapeutic realms

What You Should Know:– PathAI, a leading provider of AI-powered technology for pathology, today announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to offer Discovery’s customers enhanced, AI-enabled digital and quantitative insights from biospecimens to better inform drug and diagnostic development.– This collaboration marks a milestone as the first at-scale deployment of AI technologies into a leading commercial biobank.Transforming Pathology Workflow: PathAI and Discovery Life Sciences Partner to Advance Precision MedicinePathAI and Discovery Life Sciences have entered a strategic partnership to integrate PathAI’s AISight® Image Management System (IMS), ArtifactDetect, and TumorDetect products into Discovery’s global biospecimens business. This collaboration aims to revolutionize traditional pathology workflows by automating routine tasks, enabling pathologists to dedicate more time to complex analyses, and empowering Discovery’s customers with enhanced tissue-level quantitative insights.Key Highlights of the Partnership:Automation of Pathology Workflows: PathAI’s advanced AI-driven tools will significantly reduce manual workload, saving time and increasing efficiency.PathAI’s advanced AI-driven tools will significantly reduce manual workload, saving time and increasing efficiency. Enhanced Data Quality: Discovery will provide customers with standardized, structured data and deeper tissue-level insights, improving the quality of research outputs.Discovery will provide customers with standardized, structured data and deeper tissue-level insights, improving the quality of research outputs. Custom AI-Driven Solutions: The partnership includes the development of a proprietary AI-driven tissue analysis panel exclusive to Discovery, advancing translational research and biomarker discovery for biopharma partners.Expanding AI-Driven InnovationsThis partnership extends beyond Discovery’s biospecimens business to include potential applications within Discovery’s Specialty Lab Services. These AI-driven solutions are expected to accelerate drug development and precision medicine by providing advanced insights for biopharma research initiatives.Advancing Precision Medicine and DiagnosticsWith increasing investments in immuno-oncology and antibody-drug conjugates, the demand for precise diagnostic tools that optimize patient selection continues to grow. By combining PathAI’s cutting-edge technology with Discovery’s structured, multi-modal datasets, the partnership aims to:Accelerate the development of new assays and diagnostic tools.Enhance the reliability and speed of biomarker discovery.Improve patient outcomes through advanced diagnostic precision.Leadership Perspective“Our digital pathology solutions will enable Discovery Life Sciences to provide unparalleled accuracy and speed in pathology assessments, ultimately benefiting their customers with enhanced data quality and insights,” said Andy Beck, CEO of PathAI